A Randomized, Open-label Study to Characterize the Pharmacokinetics of Inhaled Oxytocin (GR121619) Compared With IM Oxytocin in Women in the Third Stage of Labour, and With IV Oxytocin in Non-pregnant, Non-lactating Women of Childbearing Potential

Trial Profile

A Randomized, Open-label Study to Characterize the Pharmacokinetics of Inhaled Oxytocin (GR121619) Compared With IM Oxytocin in Women in the Third Stage of Labour, and With IV Oxytocin in Non-pregnant, Non-lactating Women of Childbearing Potential

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Oxytocin (Primary) ; Oxytocin (Primary) ; Oxytocin (Primary)
  • Indications Postpartum haemorrhage
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Oct 2017 Planned End Date changed from 30 Nov 2017 to 29 Dec 2017.
    • 09 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 29 Dec 2017.
    • 31 Aug 2017 Planned End Date changed from 30 Sep 2017 to 30 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top